AGILE THERAPEUTICS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.4 USD | 0.00% |
|
+5.26% | -79.49% |
| Mar. 28 | Transcript : Agile Therapeutics, Inc., Q4 2023 Earnings Call, Mar 28, 2024 | |
| Mar. 28 | Earnings Flash (AGRX) AGILE THERAPEUTICS Posts Q4 Revenue $3.6M | MT |
Valuation
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 19.8 | 148.3 | 250.9 | 59.25 | 9.219 | 4.898 |
| Enterprise Value (EV) 1 | 11.95 | 113.9 | 213 | 57.9 | 6.184 | 4.513 |
| P/E ratio | -1 x | -6.64 x | -4.69 x | -0.63 x | -0.19 x | -0.29 x |
| Yield | - | - | - | - | - | - |
| Capitalization / Revenue | - | - | 335,027,477 x | 14,448,522 x | 847,068 x | 249,974 x |
| EV / Revenue | - | - | 284,357,250 x | 14,119,090 x | 568,219 x | 230,324 x |
| EV / EBITDA | -0.65 x | -6.1 x | -4.37 x | -0.84 x | -0.15 x | -0.23 x |
| EV / FCF | -1.17 x | -13 x | -7.68 x | -1.49 x | -0.26 x | -1.23 x |
| FCF Yield | -85.6% | -7.71% | -13% | -67.3% | -387% | -81.6% |
| Price to Book | 0.98 x | 3.82 x | 5.09 x | 6.39 x | -1.76 x | -0.35 x |
| Nbr of stocks (in thousands) | 17.2 | 29.7 | 43.7 | 60.7 | 812 | 2,512 |
| Reference price 2 | 1,152 | 5,000 | 5,740 | 976.2 | 11.35 | 1.950 |
| Announcement Date | 3/12/19 | 2/20/20 | 3/1/21 | 3/30/22 | 3/23/23 | 3/28/24 |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net sales | - | - | 0.749 | 4.101 | 10.88 | 19.59 |
| EBITDA 1 | -18.49 | -18.7 | -48.78 | -68.78 | -39.9 | -19.5 |
| EBIT 1 | -18.52 | -18.86 | -49.05 | -71 | -41.43 | -19.88 |
| Operating Margin | - | - | -6,549.13% | -1,731.41% | -380.69% | -101.49% |
| Earnings before Tax (EBT) 1 | -20.26 | -18.61 | -51.85 | -74.89 | -30.09 | -14.46 |
| Net income 1 | -19.78 | -18.61 | -51.85 | -74.89 | -25.41 | -14.46 |
| Net margin | - | - | -6,922.96% | -1,826.24% | -233.48% | -73.83% |
| EPS 2 | -1,153 | -752.8 | -1,225 | -1,543 | -59.00 | -6.710 |
| Free Cash Flow 1 | -10.23 | -8.787 | -27.74 | -38.95 | -23.95 | -3.682 |
| FCF margin | - | - | -3,703.91% | -949.66% | -220.03% | -18.79% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 3/12/19 | 2/20/20 | 3/1/21 | 3/30/22 | 3/23/23 | 3/28/24 |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 1.287 | 1.514 | 1.761 | 2.126 | 3.002 | 3.996 | 3.813 | 5.503 | 6.662 | 3.615 |
| EBITDA | - | - | - | - | - | - | - | - | - | - |
| EBIT 1 | -15.77 | -22.36 | -15.57 | -11.4 | -18.71 | -6.876 | -6.708 | -5.126 | -4 | -4.05 |
| Operating Margin | -1,225.64% | -1,476.88% | -884.33% | -536.12% | -623.18% | -172.07% | -175.92% | -93.15% | -60.04% | -112.03% |
| Earnings before Tax (EBT) 1 | -16.77 | -23.36 | -16.44 | -12.22 | -19.67 | -3.929 | -5.39 | -3.809 | -0.799 | -4.467 |
| Net income 1 | -16.77 | -23.36 | -11.77 | -12.22 | -19.67 | -3.929 | -5.39 | -3.809 | -0.799 | -4.467 |
| Net margin | -1,303.19% | -1,542.8% | -668.31% | -574.74% | -655.1% | -98.32% | -141.36% | -69.22% | -11.99% | -123.57% |
| EPS 2 | -360.0 | -400.0 | -189.0 | -135.5 | -26.50 | -5.000 | -5.910 | -2.150 | -0.2700 | -1.510 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 11/2/21 | 3/30/22 | 5/12/22 | 8/11/22 | 11/7/22 | 3/22/23 | 5/11/23 | 8/9/23 | 11/9/23 | 3/28/24 |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - |
| Net Cash position 1 | 7.85 | 34.3 | 38 | 1.35 | 3.04 | 0.39 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - |
| Free Cash Flow 1 | -10.2 | -8.79 | -27.7 | -38.9 | -23.9 | -3.68 |
| ROE (net income / shareholders' equity) | -70% | -56.5% | -109% | -256% | 3,118% | 132% |
| ROA (Net income/ Total Assets) | -31.7% | -32.8% | -50% | -79% | -96.7% | -101% |
| Assets 1 | 62.37 | 56.78 | 103.7 | 94.84 | 26.29 | 14.26 |
| Book Value Per Share 2 | 1,174 | 1,311 | 1,127 | 153.0 | -6.450 | -5.510 |
| Cash Flow per Share 2 | 457.0 | 988.0 | 330.0 | 315.0 | 6.100 | 0.8600 |
| Capex 1 | 0.32 | 0.1 | 0.35 | 0.27 | 0.13 | - |
| Capex / Sales | - | - | 47.13% | 6.56% | 1.22% | - |
| Announcement Date | 3/12/19 | 2/20/20 | 3/1/21 | 3/30/22 | 3/23/23 | 3/28/24 |
1USD in Million2USD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -79.49% | 2.74M | |
| -2.31% | 103B | |
| +0.56% | 95.28B | |
| +1.69% | 22.15B | |
| -17.37% | 21.02B | |
| -9.30% | 18.15B | |
| -41.01% | 16.74B | |
| -14.85% | 16.05B | |
| +3.21% | 13.68B | |
| +33.54% | 12.17B |
- Stock Market
- Equities
- AGRX Stock
- Financials Agile Therapeutics, Inc.
